跳至主要内容
临床试验/CTRI/2022/01/039144
CTRI/2022/01/039144招募中2 期

Clinical Investigation for the Foldax TRIA Aortic Heart Valve

FOLDAX INDIA PRIVATE LIMITED0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Is 45 years or older
  • 2. Provide written informed consent prior to trial procedures after standard of care studies and tests indicate that the patient needs aortic valve replacement
  • 3. Agrees to attend all follow-up assessments for up to month 12 and is willing to comply with specified follow-up evaluations for the FOLDAX Clinical trial
  • 4. Diagnosed with symptomatic aortic valve disease (stenosis and/or regurgitation) where aortic valve replacement is recommended based on pre-operative evaluations

排除标准

  • 1 Requires multiple valve replacement / repair
  • 2 Requires emergency surgery
  • 3 Has had prior valve surgery
  • 4 Requires a surgical procedure outside of the cardiac area
  • 5 Requires cardiac procedure other than a CABG, or aortic root enlargement (allowed to
  • optimize the fit and placement of the TRIA Heart Valve if needed).
  • 6 Requires or are planning another unrelated surgery within 12 months of undergoing
  • implantation of the study device
  • 7 Has active endocarditis/myocarditis or within 3 months to the scheduled surgery
  • 8 Has renal insufficiency as determined by creatinine (S-Cr) level as >= 1.5 mg/dl or endstage
  • renal disease requiring chronic dialysis at screening visit
  • 9 Has MRI or CT scan confirmed stroke, cerebrovascular accident (CVA) or transient
  • ischemic attack (TIA) within 3 months (90 days) prior to planned valve surgery
  • 10 Has acute myocardial infarction (Ml) within 30 days prior to planned valve surgery
  • 11 Has life expectancy to less than 12 months
  • 12 Diagnosed with hypertrophic obstructive cardiomyopathy (HOCM), except patients
  • who have isolated subaortic muscular hypertrophy diagnosed at the time of surgery
  • 13 Diagnosed with abnormal calcium metabolism and/or hyperparathyroidism
  • 14 Echocardiographic left ventricular ejection fraction <25%
  • 15 Echocardiographic evidence of an intra-cardiac thrombus or vegetation
  • 16 Hemodynamic or respiratory instability requiring inotropic support, mechanical
  • circulatory support, or mechanical ventilation within 30 days prior to planned valve
  • 17 Documented leukopenia (WBC < 4.0 x 103/μL), acute anemia (Hgb < 10.0 gm/dl or 6 mmol/L), thrombocytopenia (platelet count < 100 x103/μL) or history of bleeding diathesis or coagulopathy
  • 18 Has prior organ transplant or is currently an organ transplant candidate
  • 19 Current or recent participation (within 6 weeks prior to surgery) in another drug or device trial
  • 20 Pregnant, lactating or planning to become pregnant during the duration of participation in trial
  • 21 Currently incarcerated or unable to give voluntary informed consent
  • 22 Documented history of substance (drug or alcohol) abuse within the last 5 years prior to implant
  • 23 Requires concomitant left ventricular assist device (LVAD) placement, Impella placement, and/or intra-aortic balloon pump
  • 24 Tests positive for an active infection with SARS-CoV-2 (COVID-19)
  • 25 Currently diagnosed as uncontrolled diabetes mellitus (Random BSL > 300 mg/dl)

研究者

发起方
FOLDAX INDIA PRIVATE LIMITED

相似试验

This trial is related to replacement of diseased... | 临床试验